This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colorectal cancer. The names of the potential treatments involved in this study are: - Active surveillance - FOLFIRI treatment
Name: FOLFIRI Protocol
Description: FOLFIRI, a cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.Type: DrugctDNA-POSITIVE: FOLFIRI Protocol
Name: ACTIVE SURVEILLANCE
Description: Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collectionsType: OtherctDNA-POSITIVE: ACTIVE SURVEILLANCE ctDNA-NEGATIVE: ACTIVE SURVEILLANCE
Description: Disease-free survival (DFS) between ctDNA-positive patients treated treated with additional adjuvant therapy and ctDNA-positive patients who are untreated
Measure: Disease-free survival (DFS) Time: 5 yearsDescription: Compare the clearance rate of ctDNA in ctDNA-positive patients between patients treated with additional adjuvant therapy and those who are untreated
Measure: Clearance rate of ctDNA Time: 7 MonthsDescription: Overall survival (OS) between ctDNA-positive patients treated with additional adjuvant therapy and ctDNA-positive patients who are untreated
Measure: Overall Survival (OS) Rate Time: 5 yearsAllocation: Randomized
Parallel Assignment
There is one SNP
KRAS c.35G>A vs. KRAS G12D). --- G12D ---